Unraveling preeclampsia: Is the fibrinogen‐to‐albumin ratio the key to early risk assessment?
The FAR is a promising biomarker for the early prediction of preeclampsia, its severity, and adverse perinatal outcomes. Given its accessibility, affordability, and strong predictive value, FAR could be integrated into first-trimester screening protocols alongside existing markers to improve early risk stratification. Further multi-center validation studies are recommended to optimize predictive models for clinical use.
Authors
- Esra Karataş (ORCID: https://orcid.org/0000-0003-3474-2398)
- Dilek Şahın (ORCID: https://orcid.org/0000-0001-8567-9048)
- Özgür Kara (ORCID: https://orcid.org/0000-0002-4204-0014)
- Uğurcan Zorlu (ORCID: https://orcid.org/0000-0002-8912-0812)
- Hakkı Şerbetçi (ORCID: https://orcid.org/0000-0001-6536-8138)
- Atakan Tanaçan (ORCID: https://orcid.org/0000-0001-8209-8248)
- Osman Onur Özkavak (ORCID: https://orcid.org/0000-0001-9259-7825)
- Gülcan Okutucu (ORCID: https://orcid.org/0000-0003-4618-8312)
Institutions
- Ankara University (TR)
- Memorial Ankara Hospital (TR)
- Başkent University Hospital (TR)
- Sağlık Bilimleri Üniversitesi (TR)
Publication Details
- Journal
- International Journal of Gynecology & Obstetrics
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/ijgo.70510
- Citations
- 2
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 4.11